AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Phase 2 Completed 46 enrolled Eastern Cooperative Oncology Group National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.

Timeline

Start: 2008-11-07
Primary completion: 2014-10
Completion: 2015-04

Outcome

Met primary endpoint

paper CONCLUSION: Motesanib (AMG 706) demonstrated a 4-month PFS that met the per-protocol definition of efficacy. PMID 29853660 ↗

registry analysis (unspecified test); AMG 706+Octreotide; p <0.001; one sample binomial test NCT00427349 ↗

Publications

Lubner S, Feng Y, Mulcahy M, O'Dwyer P, Giang GY, Hinshaw JL, Deming D, Klein L, Teitelbaum U, Payne J, Engstrom P, Stella P, Meropol N, Benson A. E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist. 2018 Sep;23(9):1006-e104. doi: 10.1634/theoncologist.2018-0294. Epub 2018 May 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	motesanib	Small molecule	125 mg	Oral
Background	Octreotide	Peptide	30 mg	Intramuscular